The American Journal of Managed Care

Subcutaneous Trastuzumab Induces Immune Function in HER2+ Breast Cancer

Targeted Oncology ™ originally published this article. This version has been lightly edited. Subcutaneous (SC) trastuzumab induced stromal tumor infiltrating lymphocyte (sTIL) enrichment and favorably ...
ascopubs.org

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

To Tell or Not to Tell: The Community Wants to Know About Expensive Anticancer Drugs As a Potential Treatment Option At least five potential extracellular and intracellular antitumor mechanisms of ...
Targeted Oncology

New-Generation ADC Elicits Responses in Neoadjuvant HER2+ Breast Cancer

The bispecific HER2-directed antibody-drug conjugate (ADC) TQB2102 has demonstrated robust antitumor activity and a positive safety profile in the phase 2 TQB2102-II-01 trial (NCT06198751), showing ...

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class ...